The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. (Q30359348)

20 June 2017

The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. (English)

1 reference

20 June 2017

1 reference

Jeff Boyle

1

1 reference

20 June 2017

Donna Eastman

2

1 reference

20 June 2017

Christine Millar

3

1 reference

20 June 2017

Sarina Camuglia

4

1 reference

20 June 2017

John Cox

5

1 reference

20 June 2017

Martin Pearse

6

1 reference

20 June 2017

Jeremy Good

7

1 reference

20 June 2017

Debbie Drane

8

1 reference

20 June 2017

language of work or name

English

0 references

publication date

29 December 2006

1 reference

20 June 2017

1 reference

20 June 2017

25

1 reference

20 June 2017

14

1 reference

20 June 2017

2541-2544

1 reference

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

20 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Iscoms Containing PurifiedQuillajaSaponins Upregulate both Th1-like and Th2-like Immune Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Immunomodulation by iscoms, immune stimulating complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Immune responses to ISCOM formulations in animal and primate models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Induction of lymphocyte recruitment in the absence of a detectable immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Interactions between Immune-Stimulating Complexes (ISCOMs) and Peritoneal Mononuclear Leucocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Studies on experimental adjuvanted influenza vaccines: comparison of immune stimulating complexes (Iscoms) and oil-in-water vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.12.018

10.1016/J.VACCINE.2006.12.018

7 January 2021

Identifiers

DOI

1 reference

20 June 2017

1 reference